Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683922 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP3A4SMN1; SMN2RXFP1TP53 | |
| SCHEMBL683984 | 0.84 | RXFP1 (0.63) | CYP1A2CYP3A4SMN1; SMN2RXFP1TP53 | |
| SCHEMBL684286 | 0.84 | RXFP1 (0.52) | CYP1A2CYP3A4SMN1; SMN2RXFP1TP53 | |
| SCHEMBL683921 | 0.83 | RXFP1 (0.68) | SMN1; SMN2RXFP1TP53ADORA2BLMNA | |
| SCHEMBL683985 | 0.82 | ALOX15 (0.56) | SMN1; SMN2RXFP1TP53ADORA2BLMNA | |
| SCHEMBL25395304 | 0.82 | RXFP1 (0.57) | CYP1A2CYP3A4SMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL683913 | 0.82 | RXFP1 (0.55) | CYP1A2CYP3A4SMN1; SMN2RXFP1TP53 | |
| Fenethylline SCHEMBL149145 | 0.81 | ALDH1A1 (0.65) | SMN1; SMN2RXFP1ADORA2BLMNAMAPT | |
| Fenethylline SCHEMBL121386 | 0.81 | ALDH1A1 (0.64) | SMN1; SMN2RXFP1ADORA2BLMNAMAPT | |
| SCHEMBL684285 | 0.81 | RXFP1 (0.53) | SMN1; SMN2RXFP1ADORA2BLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | CYP1A2 4049/4885CYP3A4 4777/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.